Success Metrics

Clinical Success Rate
94.6%

Based on 35 completed trials

Completion Rate
95%(35/37)
Active Trials
3(6%)
Results Posted
23%(8 trials)
Terminated
2(4%)

Phase Distribution

Ph phase_3
10
20%
Ph phase_4
5
10%
Ph not_applicable
6
12%
Ph phase_2
7
14%
Ph phase_1
19
38%

Phase Distribution

19

Early Stage

7

Mid Stage

15

Late Stage

Phase Distribution47 total trials
Phase 1Safety & dosage
19(40.4%)
Phase 2Efficacy & side effects
7(14.9%)
Phase 3Large-scale testing
10(21.3%)
Phase 4Post-market surveillance
5(10.6%)
N/ANon-phased studies
6(12.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

92.1%

35 of 38 finished

Non-Completion Rate

7.9%

3 ended early

Currently Active

3

trials recruiting

Total Trials

50

all time

Status Distribution
Active(4)
Completed(35)
Terminated(3)
Other(8)

Detailed Status

Completed35
unknown7
Recruiting3
Terminated2
Withdrawn1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
50
Active
3
Success Rate
94.6%
Most Advanced
Phase 4

Trials by Phase

Phase 119 (40.4%)
Phase 27 (14.9%)
Phase 310 (21.3%)
Phase 45 (10.6%)
N/A6 (12.8%)

Trials by Status

recruiting36%
unknown714%
withdrawn12%
terminated24%
not_yet_recruiting12%
completed3570%
suspended12%

Recent Activity

Clinical Trials (50)

Showing 20 of 50 trialsScroll for more
NCT06969287Phase 3

Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery

Recruiting
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT04510194Phase 3

COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)

Completed
NCT07359482Phase 3

sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19

Not Yet Recruiting
NCT05874037Phase 2

Fluvoxamine for Long COVID-19

Completed
NCT04885530Phase 3

ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
NCT06821698Phase 1

To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers

Completed
NCT04539951Phase 2

Pragmatic Trial of Obsessive-compulsive Disorder

Recruiting
NCT06232109Phase 1

Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

Completed
NCT05894564Phase 3

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)

Completed
NCT02853136Phase 1

Influence of Fluvoxamine on the Pharmacokinetics of BI 409306

Completed
NCT02893371

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
NCT05890586Phase 3

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)

Completed
NCT05888207Phase 1

A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects

Completed
NCT03779789Phase 4

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment

Completed
NCT05712265Phase 1

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Completed
NCT04668950Phase 3

Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)

Completed
NCT02022709Phase 4

Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients

Completed
NCT04718480Phase 2

Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients

Completed
NCT04160377Phase 2

A Clinical Trial of Fluvoxamine for Melancholia

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
50